Printer Friendly

Articles from M2 Pharma (July 17, 2019)

1-27 out of 27 article(s)
Title Author Type Words
Alzamend Neuro Names McDade to Its Scientific Advisory Board. 842
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3. 387
AstraZeneca's Imfinzi Granted orphan drug designation. 139
AVROBIO expects USD120.25m from public offering of common stock. 237
Avrobio Eyes USD 100m Raise from Common Stock Offering. 313
Baxter's board announces USD0.22 per share dividend pay order. 116
BioPharmX names new chief operating officer. 109
BioPharmX names Steven M. Bosacki as COO. 139
Cancer Targeted Technology Starts Phase I Clinical Trial in Prostate Cancer Patients with an Innovative Radiotherapy, CTT1403, and Receives a USD 3.2m NIH Grant to Fund the Trial. 355
CellaVision's profit up in Q2 2019. Financial report 149
Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer. 599
First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder. 310
Genmab reports net sales of DARZALEX up by 51% in Q2 2019. Financial report 217
Immusoft Names Hayes as Chief Scientific Officer. 553
Immusoft names Robert Hayes, PhD as chief scientific officer. 135
Parvus Therapeutics Names Rienhoff as Chairman. 400
Protagonist Therapeutics grants stock options at USD13.15 per share. 152
Puma Biotechnology announces receipt by licensing partner of regulatory approval from Health Canada to commercialise NERLYNX for extended adjuvant treatment of HER2-positive early stage breast cancer. 343
Q'Apel Medical wins US FDA clearance for Walrus Balloon Guide Catheter. 133
Recordati signs contract with Novartis for worldwide rights to Signifor and Signifor LAR. 217
Seattle Genetics and Astellas Submit Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer. 549
Seattle Genetics incurs net loss of USD79.2m in Q2 2019. Financial report 183
Sobi's board exercises authorisation for repurchase of class C shares. 302
TrialCard names new chief financial officer. 132
US FDA grants breakthrough Therapy Designation to Dicerna Pharmaceuticals' DCR-PHXC. 166
Verm Publishes New Study Demonstrating Overa's Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone. 512
ViewRay welcomes Dr Gail Wilensky to board. 180

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |